Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Bayer expands birth control business with Conceptus purchase

Authored by James Sheppard

Bayer recently announced that they had completed the purchase of USA based Conceptus for $1.1bn in cash. The $31 per share offer was a 20% premium on the closing share price. The purchase gives Bayer access to Conceptus approved birth control product Essure.

Essure was approved by the FDA in 2002 and is a set of coils that are inserted into fallopian tubes to stop conception. The product will join Bayer’s intrauterine devices, Mirena and the recently approved Skyla. The inter-uterine devices are designed to be used for several years at a time, while Essure is a permanent option.

Conceptus is also currently awaiting approval in Europe for a birth-control patch and another product in late stage development. Bayer currently has a multi-million dollar contraceptive pill business which has recently run into trouble with generic competition and safety concerns. Bayer recently announced they had set aside 1.19bn Euros to cover litigation related to its contraceptive business.

 

Despite the setbacks, Bayer’s contraceptive business brought in revenues of 1.916bn Euros in 2012. The Conceptus purchase will fit into Bayer’s contraceptive business and shore up the segment and help to offset the decline seen by a rise in generic competition.

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Head Office
Liftstream Ltd.
111 Buckingham Palace Road,
London,
SW1W 0SR
   Tel: ​+44 (0)20 3180 5880
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap